news – Page 5666 – pharmaceutical daily

December 30, 2016 Off

Corporate makeovers drive corporate takeovers in 2016 M&A bonanza

In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.

December 30, 2016 Off

Eurofins buys another research company in Spain

By Dino Mustafić

Analytical company Eurofins Scientific has broadened its testing facilities in Spain, as it is about to buy a Spanish pharmaceutical company Villapharma Research SL.

December 29, 2016 Off

argenx publishes data from acute myeloid leukemia drug study

By Dino Mustafić

Argenx (argenx) is currently working on a therapy for the treatment of acute myeloid leukemia (AML), and during the holiday season, the company has revealed how it is going.

December 28, 2016 Off

Sanofi sues Novo Nordisk over diabetes drug in the U.S.

By Dino Mustafić

France’s Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.

December 27, 2016 Off

Seattle Genetics’ cancer drug put on clinical hold after four deaths

By Dino Mustafić

Seattle Genetics Inc said four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage studies.

December 27, 2016 Off

Shire’s Adynovate cleared for young children haemaphilia patients

By Dino Mustafić

Shire will now be able to use its Adynovate for treating heamophilia A in children younger than 12 years of age, as the the U.S. Food and Drug Administration (FDA) has approved it for that age group. The FDA has also…

December 27, 2016 Off

Beijing buyers club? China’s cancer patients gamble on gray market

By Dino Mustafić

When her father’s lung cancer worsened, Yin Min, a 51-year-old financial broker from Shanghai, faced a choice: pay nearly $3,000 a month for an approved drug or pay a fraction of the price for a generic drug not approved for use in China.

December 23, 2016 Off

Cardinal Health in $10 million U.S. settlement over painkiller orders

By Dino Mustafić

A drug distributor owned by Cardinal Health Inc has agreed to pay $10 million to resolve claims that it failed to alert the U.S. Drug Enforcement Administration to suspicious orders of addictive painkillers by New York-area pharmacies.

December 23, 2016 Off

Israeli’s largest drugmaker Teva agrees to pay U.S. government $519M over foreign bribery charges

By Dino Mustafić

Israeil’s largest drugmaker Teva Pharmaceuticals Industries has settled with the United States government over international bribery of government officials in…

December 23, 2016 Off

TiGenix submits Day 120 Responses to EMA for Crohn`s disease drug

By Dino Mustafić

TiGenix has submitted its responses to the European Medicines Agency`s (EMA) Day 120 List of Questions for Cx601, its lead…